Skip to content
Review Open access

Probiotic-Derived Extracellular Vesicles as Potential Nano-Immunotherapeutic Platforms in IBD: A Clinician’s Perspective

Sep 2026 · International Journal of Nanomedicine · Vol 21 · 0 citations · 200 references
Medicine

TL;DR

A comprehensive overview of probiotic-derived EVs, including their biogenesis, classification, and molecular composition, is provided, with a focus on barrier regulation, immune modulation, and microbial homeostasis in IBD.

Abstract

Abstract Inflammatory bowel disease (IBD) is a chronic, relapsing inflammatory disorder driven by complex interactions. Despite therapeutic advances, achieving sustained remission remains difficult, underscoring the need for safer and more durable treatment strategies. Increasing evidence highlights the pivotal role of the gut microbiota in IBD pathogenesis, prompting growing interest in microbiome-based interventions. Probiotic-derived extracellular vesicles (probiotic-derived EVs), a subset of bacterial EVs (BEVs), have emerged as promising cell-free mediators of host–microbe communication. These nanoscale vesicles can deliver bioactive cargo, modulate immune responses, and influence epithelial barrier function, thereby offering a potential strategy to regulate intestinal homeostasis while potentially avoiding some limitations associated with live microbial therapies. This review provides a comprehensive overview of probiotic-derived EVs, including their biogenesis, classification, and molecular composition. It further examines their biological functions and mechanisms of action in IBD, with a focus on barrier regulation, immune modulation, and microbial homeostasis. Recent advances in engineering strategies to enhance therapeutic efficacy are also summarized. Key challenges for clinical translation, including standardization, safety concerns, and limited clinical validation despite promising preclinical findings, are discussed. Together, these mechanistic and translational perspectives help delineate the current evidence, remaining limitations, and future directions regarding the development of probiotic-derived EVs as nanotherapeutic platforms for IBD.

Read PDF

Similar papers

Review Open access Sep 2026

Hydrogel-based Probiotic Delivery Systems for Gut Microbiota and Homeostasis Regulation from Bench to Bedside

The modulation of gut microbiota is critical for intestinal homeostasis and addressing disorders such as inflammatory bowel disease (IBD) and colorectal cancer (CRC). Probiotics have gained attention for maintaining gut health, but ensuring their survival until reaching the target intestinal area remains a significan...

Xue-Qing Chen, L. Du, Jie Shen et al. · 0 citations
Review Open access Sep 2026

The Role and Therapeutic Potential of Gut Microbiota and Their Extracellular Vesicles in Neurological, Cardiovascular, and Metabolic Diseases.

Current evidence regarding the role of gut microbiota-derived EVs in representative neurological, cardiovascular, and metabolic diseases is summarized, highlighting both their detrimental and beneficial effects.

Zhi-Ying Rao, Lin-Wei Li, Ying Liang et al. · 0 citations
Review Open access Oct 2026

Engineering extracellular vesicles for inflammatory bowel disease and colitis-associated colorectal cancer: from therapeutic innovation to clinical translation

Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder that increases the risk of colitis-associated colorectal cancer (CAC). Despite major advances in biologics and small-molecule therapies, many patients experience primary or secondary treat...

Min-Rui Huang, Jin-Tao Yuan, Peter Muro et al. · 0 citations
Review Oct 2026

Recent advances in antioxidant nanozymes for the treatment of inflammatory bowel disease.

To overcome biopharmaceutical bottlenecks, an overview of nanozyme-based intelligent delivery platforms tailored for the inflamed gut are provided, covering endogenous/exogenous stimuli-responsive, biomimetic, and microbiota-mediated systems.

Zuo-Yi Shen, Shi-Qiao Rui, Jing-Qi Zhang et al. · 0 citations
Review Aug 2026

Extracellular vesicles in inflammatory bowel disease: from immune regulation and barrier repair to precise transformation.

Extracellular vesicles (EVs) have been shown to be key regulators of intestinal homeostasis and inflammatory responses, offering new insights into the pathogenesis of inflammatory bowel disease (IBD) and the development of targeted therapeutic strategies. EVs in the intestine can be secreted by intestinal epithelial ce...

Yiyi Lv, Qian Yang, Xi-Xi Cai et al. · 0 citations
Review Open access Sep 2026

Extracellular vesicle-based therapies in IBD: immunomodulation, regeneration, and translation

Inflammatory bowel disease (IBD) is sustained by dysregulated mucosal immune activation, maladaptive immune-cell crosstalk, epithelial barrier failure, and impaired tissue repair. This narrative review critically evaluates unmodified native mammalian EVs, donor-conditioned EVs, milk-derived EVs, post-isolation engineer...

En-Hui Lu, Min-Li Sun, Hai Meng et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.